{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:43:13Z","timestamp":1776411793843,"version":"3.51.2"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.amjcard.2006.11.019","type":"journal-article","created":{"date-parts":[[2006,11,29]],"date-time":"2006-11-29T16:26:52Z","timestamp":1164817612000},"page":"S32-S34","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S1","title":["Expert Commentary: Niacin Safety"],"prefix":"10.1016","volume":"99","author":[{"given":"B. Greg","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2006.11.019_bib1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0003-9861(55)90070-9","article-title":"Influence of nicotinic acid on serum cholesterol in man","volume":"54","author":"Altschul","year":"1955","journal-title":"Arch Biochem"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.019_bib2","doi-asserted-by":"crossref","first-page":"22C","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy","volume":"99","author":"Guyton","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.019_bib3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0026-0495(85)90092-7","article-title":"Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin","volume":"34","author":"Knopp","year":"1985","journal-title":"Metabolism"},{"key":"10.1016\/j.amjcard.2006.11.019_bib4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9149(98)00448-2","article-title":"Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia","volume":"82","author":"Guyton","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.019_bib5","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0026-0495(98)90284-0","article-title":"Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia","volume":"47","author":"Knopp","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.amjcard.2006.11.019_bib6","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.282.24.2340","article-title":"Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials","volume":"282","author":"LaRosa","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.019_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.019_bib8","first-page":"IV-197","article-title":"Frequency and importance of conversion to large buoyant LDL with simvastatin and niacin therapy: comparison of four methods","volume":"108","author":"Brown","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.019_bib9","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.1995.03530220037029","article-title":"Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a)","volume":"274","author":"Maher","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.019_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials","volume":"45","author":"Stroes","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.019_bib11","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.019_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0002-9149(97)00303-2","article-title":"Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg\/dl in patients with hyperlipidemia and coronary artery disease","volume":"80","author":"Brown","year":"1997","journal-title":"Am J Cardiol"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.019_bib13","first-page":"I-635","article-title":"Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year Familial Atherosclerosis Treatment Study (FATS) follow-up","volume":"98","author":"Brown","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.019_bib14","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.019_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-142-2-200501180-00008","article-title":"A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events","volume":"142","author":"Whitney","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2006.11.019_bib16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.amjcard.2003.10.009","article-title":"Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (the HDL Atherosclerosis Treatment Study)","volume":"93","author":"Zhao","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.019_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.019_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0002-9343(91)90500-W","article-title":"Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the Framingham Offspring Study","volume":"90","author":"Wilson","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2006.11.019_bib19","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/01.CIR.89.3.975","article-title":"Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease","volume":"89","author":"Haskell","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.019_bib20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.ATV.0000118278.21719.17","article-title":"Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib","volume":"24","author":"Clark","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2006.11.019_bib21","unstructured":"Kos submits supplemental new drug application to FDA for new Niaspan\u00ae CF range of products [news release]. July 12, 2006. Kos Pharmaceuticals, Inc. Website. Available at: http:\/\/www.kospharm.com\/files\/7122006.pdf. Accessed July 17, 2006."},{"key":"10.1016\/j.amjcard.2006.11.019_bib22","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1172\/JCI23626","article-title":"GPR109A (PUMA-G\/HM74A) mediates nicotinic acid-induced flushing","volume":"115","author":"Benyo","year":"2005","journal-title":"J Clin Intest"},{"key":"10.1016\/j.amjcard.2006.11.019_bib23","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm824","article-title":"PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect","volume":"9","author":"Tunaru","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.amjcard.2006.11.019_bib24","doi-asserted-by":"crossref","first-page":"26649","DOI":"10.1074\/jbc.C500213200","article-title":"(d)-\u03b2-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G","volume":"280","author":"Taggart","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjcard.2006.11.019_bib25","unstructured":"Kim PS. Research overview Merck Laboratories Website. Available at: http:\/\/library.corporate-ir.net\/library\/73\/731\/73184\/items\/177359\/research1.pdf. Accessed July 24, 2006."},{"key":"10.1016\/j.amjcard.2006.11.019_bib26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.amjcard.2004.09.013","article-title":"Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)","volume":"95","author":"Canner","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.019_bib27","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial (ADVENT)","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2006.11.019_bib28","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.019_bib29","first-page":"5A","article-title":"Cholesterol and lipids in the risk of coronary artery disease\u2014the Framingham Heart Study","volume":"4","author":"Castelli","year":"1988","journal-title":"Can J Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914906022375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914906022375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T03:51:04Z","timestamp":1547178664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914906022375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0002914906022375"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2006.11.019","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}